Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

Brolucizumab is a follow-up to Novartis’ blockbuster AMD therapy Lucentis (ranibizumab), which has been competing toe-to-toe in the AMD market with Eylea for several years. Novartis reported ...

Leerink downgraded Opthea (OPT) to Market Perform from Outperform with a price target of $1, down from $12. The firm cites the company ...

The FDA has approved Susvimo for the treatment of people with wet AMD who have previously responded to at least two anti-VEGF drugs such as Lucentis or Bayer and Regeneron's rival Eylea (aflibercept).

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...

Annual Report/Annual ResultsFormycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position 27.03.2025 / 06:30 CET/CESTThe ...

The trial design is similar to the most recent Phase 3 trial in wet AMD that lead to the approval of EYLEA high dose and VABYSMO. The design applies the redosing criteria generally utilized in ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

The lens will be available with the Monarch IV manual delivery system in Q2 and the AutonoMe Automated Pre-Loaded Delivery System in Q3.